Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance with optimistic guidance, including a projected revenue growth of 42% to 47% for Q3 2025 and a robust full-year growth outlook. The company is expanding into new markets and specialties, indicating future growth potential. Despite some uncertainties regarding margin contraction, the overall sentiment remains positive due to strategic investments and international expansion plans. The market cap suggests a moderate reaction, leading to a prediction of a 2% to 8% stock price increase.
Key Financial Performance
Revenue Revenue grew 49% year-over-year to nearly $600 million. The growth was driven by the introduction of new innovative offerings and broadening the range of specialties supported.
Adjusted EBITDA Adjusted EBITDA grew more than 50% year-over-year to $78 million, with margins above 13%. This was achieved through significant leverage on marketing spend and benefits from higher retention and acquisition gains.
Subscriber Base The subscriber base increased sequentially by more than 30,000, reflecting a year-over-year growth rate of 20%. Excluding the impact of the sexual health transition, subscribers grew north of 40% year-over-year.
Gross Margins Gross margins declined over 2 points quarter-over-quarter to 74%. This was due to shorter shipping cadences for certain weight loss offerings, which resulted in lower intra-quarter revenue recognized per shipment.
Cash Flow from Operations Cash flow from operations was $149 million, translating into free cash flow of $79 million. This was supported by strong cash flow and balance sheet strength.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Personalized solutions: Subscribers using personalized solutions grew 50% year-over-year, driving nearly 50% in year-over-year revenue growth.
Weight loss specialty: Launched nearly 2 years ago, combining reliable access to medications with digital tools and clinical guidance. Recently reduced prices for compounded GLP-1 treatment plans by up to 20% and introduced microdosing options for semaglutide treatments.
Hormonal care: Partnership with Marius Pharmaceuticals to offer FDA-approved oral testosterone treatments in 2026. Launched low testosterone and menopause offerings, addressing significant gaps in hormonal health care.
Diagnostics and proactive health: Plan to launch comprehensive whole-body lab testing by year-end, enabling proactive health management. Strategic investment in GRAIL for advanced multi-cancer early detection tests.
International expansion: Acquisition of Zava Global to serve customers in the U.K., Germany, France, Ireland, and Spain, reaching a market of over 200 million adults. Preparing to launch in Canada, with potential $1 billion annual revenue from international markets.
Verticalization of compounding infrastructure: Investments in facilities to ensure high standards of safety, quality, and affordability. Expanded facility footprint to over 1 million square feet by year-end.
Technology investments: Enhancing customer experience with AI tools, chatbots, and data-driven treatment recommendations. Investments in engineering and product talent.
Partnerships and investments: Active discussions with Novo Nordisk for Wegovy injections and oral treatments. Strategic investment in GRAIL for cancer detection. Partnerships to expand offerings and improve accessibility.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is subject to risks and uncertainties related to regulatory compliance, particularly in the context of FDA approvals for new treatments and compliance with health care regulations in international markets.
Supply Chain Challenges: Potential disruptions in the supply chain, especially for active pharmaceutical ingredients (APIs) and compounded treatments, could impact the availability and affordability of products.
Economic Uncertainties: Economic conditions, such as inflation or changes in consumer spending, could affect the company's ability to maintain growth and profitability.
Strategic Execution Risks: The company faces risks in executing its strategic initiatives, including the transition to personalized daily treatment offerings and the expansion into new specialties and international markets.
Competitive Pressures: The company operates in a highly competitive market, which could impact its ability to attract and retain customers.
Operational Risks: Investments in new facilities and technologies may not yield the expected returns, and there are risks associated with scaling operations, particularly in international markets.
Customer Retention Risks: The ongoing shift from on-demand to personalized offerings may lead to short-term customer attrition, impacting revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Revenue and EBITDA Targets: The company reiterated its 2030 goals of achieving more than $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
Weight Loss Specialty: Plans to continue expanding GLP-1 offerings, including microdosing options for compounded semaglutide treatments. Investments in compounding infrastructure aim to improve safety, quality, and affordability. Prices for compounded GLP-1 treatment plans were reduced by up to 20% to broaden accessibility.
New Specialties and Offerings: The company launched low testosterone and menopause offerings, with the Hers brand targeting $1 billion in annual revenue by 2026. Plans to launch comprehensive whole-body lab testing by year-end 2025, enabling proactive health management.
Longevity Specialty: Plans to launch a longevity specialty in 2026, featuring therapies like peptides, coenzymes, and GLP/GIP treatments aimed at improving performance, recovery, and cardiometabolic markers.
International Expansion: The company is expanding into Canada and scaling operations in Europe, targeting a total addressable market of over 200 million adults. International markets are expected to contribute over $1 billion in annual revenue in the long term.
Technology and Diagnostics: Plans to enhance diagnostic capabilities, including blood testing, to enable proactive health management. Investments in AI-assisted tools and data-driven treatment recommendations are underway.
Financial Outlook for 2025: Revenue is expected to be between $2.335 billion and $2.355 billion, reflecting a year-over-year increase of 58%-59%. Adjusted EBITDA is projected to range from $307 million to $317 million, with a 13% margin at the midpoint.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the timeline to release a full stack subscription service that includes at-home testing and additional products and services like peptides and a broader longevity offering? What are the biggest hurdles for this type of rollout?
A:The whole body lab testing will launch very soon before the year-end, and the longevity specialty will come to market in 2026. The longevity specialty will include treatments like peptides, coenzymes, GLP, and GIP treatments. The company is also leveraging its California-based peptide manufacturing plant to support this rollout.
Q:How confident are you that you'll be able to reaccelerate core growth over the coming quarters? What specific levers can you pull, and what's the realistic timeline to see these results?
A:The company is confident in reaccelerating growth, citing new specialties like testosterone for Hims and menopause and longevity for Hers. They also see opportunities in international markets and lab diagnostics. Growth acceleration is expected in the second half of the year.
Q:As diagnostic capabilities ramp up, how do you envision the pace in which you provide personalized treatments and expand into new specialties changes? How might you adjust your marketing efforts to make more consumers aware of this expanded offering?
A:The pace of bringing new products to market will accelerate due to better understanding of nutrient deficiencies and genetic risk markers. Marketing will shift from direct marketing to broader messaging about health and wellness, aiming to transform the brand into a global platform for proactive health management.
Q:What is your approach to the portfolio of GLP-1 solutions on the platform, especially if the Novo partnership moves forward? Are there any other GLP-1 solutions that you may add to the specialty? How do you see price reductions impacting demand?
A:The company aims to offer a broad range of GLP-1 solutions, including potential partnerships with Novo for Wegovy and other next-generation GLP-1 treatments. Price reductions are expected to make these solutions more accessible, broadening the audience and driving demand.
Q:Can you touch on the cadence of new menopause products and whether growth will be driven mainly by existing products or new offerings going into 2026?
A:Growth will be driven by a mix of existing products like dermatology and weight loss, as well as new categories like hormonal health, perimenopause, longevity, and diagnostics. The Hers business is expected to maintain strong growth rates.
Q:Is it possible margins could contract year-over-year in 2026 before you see the follow-through?
A:It is too early to provide specifics for 2026, but the company is confident that investments in new capabilities and specialties will be accretive and lead to long-term margin expansion.
Q:How are you thinking about capital deployment towards buybacks versus spending on CapEx?
A:The company prioritizes investing in growth levers like personalized capabilities and international markets but will also engage in buybacks when there is a disconnect between market value and intrinsic value.
Q:What are the discussion topics holding the Novo agreement back, and what are the pros and cons of rolling out a Novo product?
A:Specific details of the Novo discussions were not disclosed. The company believes in offering a breadth of options for patients and aims to make innovative treatments affordable.
Q:Are you still on path for $725 million for the year or better, and how has the compound versus oral market developed?
A:The company is on track to achieve $725 million or more. The oral weight loss business remains robust, and GLP-1 offerings continue to show strong performance.
Q:Can you explain the $20 million to $25 million headwind related to personalized compounded GLP-1s?
A:The headwind is due to smaller shipment cadences, which affect revenue recognition. This dynamic is expected to normalize by the back half of next year as cohorts renew more frequently.
Q:How is the Hims messaging and approach resonating outside of the U.S., and what investments are needed to scale internationally?
A:The demand for better health care is consistent globally. The company is expanding into markets like Canada, Brazil, the U.K., and others, tailoring its approach to local dynamics while leveraging its scalable operating model.
Q:How will whole body lab testing be structured or integrated with other offerings, and what are the margin implications?
A:Whole body lab testing may be offered as both stand-alone diagnostics and bundled services. The company aims to verticalize infrastructure to reduce costs and use testing as a lead generator for personalized care.
Q:Has there been any change in your marketing strategy, and how are you planning for the new year?
A:The company is leveraging organic and lower-cost channels, improving retention, and optimizing marketing for new specialties and international markets. Investments will align with a one-year payback period and support long-term growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the Novo agreement discussions, citing confidentiality. They also did not provide clear guidance on whether margins could contract in 2026, stating it was too early to comment.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America presence
Canada future
Europe acquisition
FDA Novo
FDA list
FDA testosterone
UK
access care
access provider
adult
cancer
care investment
collaboration
condition health
consumer health
effort
evolution
health challenge
health concern
health platform
investment partnership
launch
longevity
offering gap
others health
people condition
piece
platform access
population
reach engagement
relationship
response
standard
supplier
symptom
term opportunity
track record
treatment plan
variety
HIMS Transcript
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Unknown5-12
The company's international revenue growth is a positive indicator, and the transition to branded products with strong retention is promising. However, the negative impact on gross margins due to restructuring costs and the unclear guidance on future margins and EBITDA dampens the outlook. Additionally, while AI and new category investments show potential, they also introduce uncertainty. Given the market cap of $4.3 billion, the stock is likely to experience a neutral movement, as the positive and negative factors balance each other out.
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Neutral3-2
Hims & Hers Health, Inc. (HIMS) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call reveals strong financial performance with a 50% revenue increase and improved margins. The company turned a net income from a loss, indicating operational improvements. Although risks are acknowledged, the positive financial metrics and strategic initiatives outweigh them. The market cap suggests moderate sensitivity to news, leading to a positive stock price prediction of 2% to 8%.
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call summary reveals strong financial performance with optimistic guidance, including a projected revenue growth of 42% to 47% for Q3 2025 and a robust full-year growth outlook. The company is expanding into new markets and specialties, indicating future growth potential. Despite some uncertainties regarding margin contraction, the overall sentiment remains positive due to strategic investments and international expansion plans. The market cap suggests a moderate reaction, leading to a prediction of a 2% to 8% stock price increase.
HIMS Slides
HIMS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
